5 active not recruiting, 4 recruiting, 2 terminated, 1 completed. 8 Phase 1, 5 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 4, Recruiting 3, Terminated 1 |
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Unresectable Breast Carcinoma: new trials by email Literature Review of Unresectable Breast Carcinoma trials Research Report on Unresectable Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer BNT323, BNT327 - Locally Advanced Breast Cancer, Unresectable Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 380 | 2025-04-23 | 2026-10-15 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| The COMPASSION Study Telehealth Hospice Visits - Breast Cancer, Metastatic Breast Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 200 | 2024-09-01 | 2025-10-09 |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 45 | 2023-08-10 | 2026-07-31 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Onvansertib + Paclitaxel In TNBC Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Antonio Giordano, MD | 50 | 2022-09-30 | 2026-02-11 |
| Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC Nab-paclitaxel, Paclitaxel, Radiation Therapy - Triple Negative Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Withdrawn | University of Colorado, Denver | 2022-01-04 | 2022-12-06 | |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Active not recruiting | Laura Huppert, MD, BA | 145 | 2019-07-08 | 2026-04-17 |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Atezolizumab, Biopsy, Bone Scan - Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 190 | 2019-04-05 | 2026-05-29 |
| Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer Biopsy, Biospecimen Collection, Carboplatin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Completed | National Cancer Institute (NCI) | 77 | 2010-06-30 | 2025-08-15 |
Breast Neoplasms (13) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (4) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Stomach Neoplasms (2) · Bone Neoplasms (1) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Inflammatory Breast Neoplasms (1)
Breast Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3)
Biopsy (6) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Paclitaxel (3) · Radiotherapy (2) · pembrolizumab (2) · trastuzumab deruxtecan (2) · 130-nm albumin-bound paclitaxel (1) · 2C4 antibody (1) · Albumin-Bound Paclitaxel (1) · CT-P6 (1) · CX 5461 (1) · Carboplatin (1) · Disulfides (1) · Docetaxel (1)
National Cancer Institute (NCI) (5) · Antonio Giordano, MD (1) · BioNTech SE (1) · Dana-Farber Cancer Institute (1) · Laura Huppert, MD, BA (1) · SystImmune Inc. (1) · University of Colorado, Denver (1) · University of Southern California (1) · University of Washington (1)
United States (13) · Canada (3) · Australia (1) · China (1) · France (1) · Georgia (1) · Italy (1) · Moldova (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Antonio C Giordano, MD, PhD (1) · Charles E Geyer (1) · Claire Smith, MD (1) · Elizabeth M. Swisher (1) · Filipa Lynce (1) · Fumito Ito, MD (1) · Jennifer Diamond, MD (1) · Jia Luo (1) · Joanne Mortimer (1) · Kanwal P Raghav (1) · Laura Huppert, MD (1) · Sarah Tannenbaum, MD, MSc (1)
UM1CA186709 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), N01CM62202 (1), N01CM62203 (1), N01CM62209 (1), P30CA033572 (1), U10CA180821 (1), U10CA180868 (1), UM1CA186688 (1)